Biomerica Seeks Massive Share Authorization Hike, Dilution Risk Looms

Ticker: BMRA · Form: DEF 14A · Filed: Oct 20, 2025 · CIK: 73290

Sentiment: bearish

Topics: Shareholder Meeting, Stock Dilution, Corporate Governance, Executive Compensation, Equity Plan, Authorized Shares, Proxy Statement

Related Tickers: BMRA

TL;DR

**BMRA is asking for a massive share authorization increase, signaling potential future dilution or strategic moves; vote carefully.**

AI Summary

BIOMERICA, INC. (BMRA) is holding its Annual Meeting on December 12, 2025, where stockholders will vote on several key proposals. The company seeks to elect five directors, approve executive compensation on a non-binding advisory basis, and ratify Haskell & White LLP as its independent auditor for fiscal year ending May 31, 2026. A significant proposal involves amending the 2024 Stock Incentive Plan to increase authorized shares by 200,000, and another critical amendment to the Articles of Incorporation would authorize the Board to increase common stock from 25,000,000 to 300,000,000 shares. As of October 17, 2025, there were 2,947,966 shares of common stock outstanding. CEO Zackary S. Irani beneficially owns 253,492 shares, representing 8.3% of the company. The proposed increase in authorized shares could facilitate future capital raises or acquisitions, but also risks significant dilution for existing shareholders.

Why It Matters

This DEF 14A filing is crucial for BMRA investors as it outlines proposals that could significantly impact shareholder value and future corporate strategy. The proposed increase in authorized common stock from 25 million to 300 million shares, a 1,100% jump, signals potential for substantial future capital raises or strategic transactions, but also carries a high risk of dilution for current shareholders. For employees, the 200,000 share increase in the 2024 Stock Incentive Plan could mean more equity compensation, aligning incentives. Competitively, having more authorized shares provides flexibility for M&A, potentially strengthening Biomerica's position in the diagnostics market.

Risk Assessment

Risk Level: high — The risk level is high due to Proposal No. 5, which seeks to increase authorized common stock from 25,000,000 to 300,000,000 shares. This 1,100% increase could lead to significant shareholder dilution if the Board issues a large number of new shares, potentially depressing stock price and reducing existing ownership percentages. Additionally, Proposal No. 4 to increase the 2024 Incentive Plan by 200,000 shares also contributes to potential dilution.

Analyst Insight

Investors should carefully evaluate Proposal No. 5 regarding the increase in authorized common stock from 25 million to 300 million shares. Consider voting 'AGAINST' this proposal if you are concerned about potential dilution, or seek further clarification from management on the specific use cases for such a substantial increase before the December 12, 2025 Annual Meeting.

Executive Compensation

NameTitleTotal Compensation
Zackary S. IraniChief Executive Officer and Director

Key Numbers

Key Players & Entities

FAQ

What are the key proposals for Biomerica's 2025 Annual Meeting?

At Biomerica's Annual Meeting on December 12, 2025, stockholders will vote on electing five directors, approving executive compensation on an advisory basis, ratifying Haskell & White LLP as auditors, increasing shares for the 2024 Stock Incentive Plan by 200,000, and a significant amendment to increase authorized common stock from 25,000,000 to 300,000,000 shares.

How many shares of common stock does Biomerica currently have outstanding?

As of the Record Date, October 15, 2025, Biomerica had an aggregate of 2,947,966 shares of its common stock, with a $0.08 par value per share, outstanding and entitled to vote.

What is the proposed increase in authorized shares for Biomerica?

Biomerica is proposing to amend its Articles of Incorporation to authorize the Board to increase the number of authorized shares of common stock from 25,000,000 to 300,000,000, representing an 1,100% increase.

Who is Biomerica's Chief Executive Officer and what is his ownership stake?

Zackary S. Irani is Biomerica's Chief Executive Officer and Director. As of October 17, 2025, he beneficially owns 253,492 shares of common stock, which represents 8.3% of the outstanding shares.

What is the potential impact of increasing authorized shares on Biomerica stockholders?

Increasing authorized shares from 25 million to 300 million could lead to significant dilution for existing stockholders if the company issues a large number of new shares. While it provides flexibility for future capital raises or strategic acquisitions, it could also reduce the value of current holdings.

When and where will Biomerica's 2025 Annual Meeting be held?

Biomerica's 2025 Annual Meeting will be held on December 12, 2025, at 10:00 a.m. Pacific Time. It will be a hybrid meeting, accessible virtually at www.virtualshareholdermeeting.com/BMRA2025 and in person at the company's offices at 17571 Von Karman Avenue, Irvine, California 92614.

What is the purpose of amending Biomerica's 2024 Stock Incentive Plan?

Biomerica proposes to amend its 2024 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under the plan by 200,000 shares. This is typically done to provide more equity compensation for employees and directors, aligning their interests with shareholders.

What is a 'broker non-vote' and how does it affect Biomerica's proposals?

A 'broker non-vote' occurs when a broker cannot vote a beneficial owner's shares on non-routine matters (like director elections or incentive plan amendments) without instructions. For Biomerica's non-routine proposals (1, 2, and 4), broker non-votes will not count as votes cast and will have no effect on the outcome. For routine matters (3, 5, and 6), brokers can vote without instructions.

Who is Biomerica's independent registered public accounting firm?

Biomerica's Board of Directors has selected Haskell & White LLP as its independent registered public accounting firm for the fiscal year ending May 31, 2026, and stockholders are asked to ratify this selection.

How can Biomerica stockholders vote at the Annual Meeting?

Biomerica stockholders can vote on the Internet, by telephone, by mail, or by attending the Annual Meeting either virtually at www.virtualshareholdermeeting.com/BMRA2025 or in person at the Irvine office. Online and telephone voting facilities are available until 11:59 p.m. Eastern Time on December 11, 2025.

Risk Factors

Industry Context

Biomerica, Inc. operates in the diagnostics and medical device industry, a sector characterized by rapid technological advancements, stringent regulatory oversight (FDA, etc.), and competitive pressures from both large established players and smaller innovative companies. The industry requires significant R&D investment and faces challenges related to market access, reimbursement, and intellectual property protection. Trends include a growing demand for point-of-care diagnostics, personalized medicine, and digital health solutions.

Regulatory Implications

As a medical device company, Biomerica is subject to rigorous regulatory requirements from bodies like the FDA. The proposed increase in authorized shares and stock incentive plan amendments, while primarily financial/corporate governance matters, could indirectly impact regulatory compliance if they lead to significant changes in operations or financial structure. The ratification of the auditor is a standard regulatory requirement.

What Investors Should Do

  1. Carefully evaluate the significant increase in authorized shares (Proposal 5) and its potential for dilution versus strategic benefits. Consider voting against or withholding for this proposal if concerns about dilution outweigh potential future growth opportunities.
  2. Review the proposed amendment to the 2024 Stock Incentive Plan (Proposal 4) and assess the impact of adding 200,000 shares on potential future dilution and employee compensation strategy.
  3. Vote on the election of directors (Proposal 1) based on their qualifications and the company's strategic direction. Note that directors are elected by a plurality vote.
  4. Consider the non-binding advisory vote on executive compensation (Proposal 2). A 'FOR' vote indicates approval of the disclosed compensation practices.
  5. Ratify the selection of Haskell & White LLP as the independent auditor (Proposal 3) to ensure continued financial oversight and compliance.

Key Dates

Glossary

DEF 14A
A filing with the SEC that provides detailed information to shareholders about matters to be voted on at an annual meeting, including director nominations, executive compensation, and other corporate actions. (This document is the proxy statement for Biomerica Inc.'s 2025 Annual Meeting, outlining the proposals and information shareholders need to vote.)
Articles of Incorporation
The foundational legal document of a corporation that outlines its basic structure, purpose, and powers, including the authorized number of shares. (An amendment to the Articles is proposed to drastically increase the authorized shares of common stock from 25,000,000 to 300,000,000.)
2024 Stock Incentive Plan
A plan established by the company to grant stock options, restricted stock, or other equity-based awards to employees and directors. (The company seeks to increase the number of shares available under this plan by 200,000, impacting future equity compensation.)
Record Date
A specific date set by the company to determine which shareholders are entitled to receive notice of and vote at a shareholder meeting. (October 15, 2025, is the record date, with 2,947,966 shares outstanding on this date.)
Par Value
A nominal value assigned to a share of stock by the company's charter, often a very small amount, distinct from its market value. (Biomerica's common stock has a par value of $0.08 per share.)
Broker Non-Vote
A situation where a broker holding shares for a beneficial owner does not vote those shares because the owner did not provide instructions on non-routine matters. (Broker non-votes will not count towards the outcome for director elections (Proposal 1) and incentive plan amendments (Proposal 4), but are expected to be minimal for auditor ratification (Proposal 3).)
Plurality Vote
A voting system where the candidate or proposal receiving the most votes is elected or approved, even if it's not a majority. (This is the voting requirement for electing directors (Proposal 1).)
Non-binding Advisory Basis
A vote by shareholders on a proposal (like executive compensation) that expresses their opinion but does not legally bind the company's board of directors. (Shareholders will vote on executive compensation (Proposal 2) on this basis.)

Year-Over-Year Comparison

This filing is a proxy statement for the 2025 Annual Meeting and does not contain comparative financial data from a prior year's proxy statement. However, it highlights a significant proposed increase in authorized shares from 25,000,000 to 300,000,000, which is a substantial change in the company's capital structure authorization. The number of outstanding shares as of October 15, 2025, was 2,947,966, and the largest individual shareholder among named executives and directors, CEO Zackary S. Irani, owns 8.3%.

Filing Stats: 4,896 words · 20 min read · ~16 pages · Grade level 11.1 · Accepted 2025-10-20 17:05:17

Key Financial Figures

Filing Documents

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 BIOMERICA, INC. (Name of Registrant as Specified in Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration (3) Filing Party: (4) Date Filed BIOMERICA, INC. 17571 Von Karman Avenue Irvine, CA 92614 NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 12, 2025 To Our Stockholders: NOTICE IS HEREBY GIVEN that the annual meeting of the stockholders of BIOMERICA, INC., a Delaware corporation (herein called the "Company" or "our"), will be held on DECEMBER 12, 2025, at 10:00 a.m., Pacific Time (the "Annual Meeting"). The Annual Meeting will be held both virtually via the internet at www.virtualshareholdermeeting.com/BMRA2025 and in person at our offices, 17571 Von Karman Avenue, Irvine, California 92614. At the meeting, you will be asked to consider and vote upon the following matters: 1. To elect five directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal. The proxy statement which accompanies this Notice includes the names of the nominees to be our Board of Directors (the "Board") for election; 2. To approve, on a non-binding advisory basis, the compensation paid to our named executive officers as disclosed in this proxy statement; 3. To ratify the selection of Haskell & White LLP as our independent registered public accounting firm for our fiscal year ending May 31, 2026; 4. To approve an amendment to our 2024 Stock Incentive Plan (the "2024 Incentive Plan") to increase the number of shares of common stock authorized for issuance under the 2024 Incentive Plan by 200,000 shares; 5. To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Articles") to authorize the Board, at their discretion, to effect an increase in the number of authorized shares of our common stock from 25,000,000 to 300,000,000; 6. To approve an adjournment of the Annual Meeting; and 7. To transact such other business which may properly come before the Annual Meeting and any adjournment thereof. You will be able to attend the Annual Meeting either virtually or in person. In accordance with the provisions of our bylaws, the Board has fixed the close of business on October 15, 2025, as the record date for the determination of the holders of our common stock, $0.08 par value per share, entitled to notice of and to vote at our Annual Meeting. In accordance with U.S. Securities and Exchange Commission (the "SEC") rules, we are providing access to our proxy materials over the Internet to our shareholders rather than in paper form. As a result, on or about October 20, 2025, we are mailing to our stockholders, other than those who previously requested electronic or paper delivery of proxy materials, a Notice of Internet Availability of Proxy Materials (the "Notice") for the fiscal year ended May 31, 2025. The Notice contains instructions on how to access those documents over the Internet. The Notice also contains instructions on how to request a paper copy of our proxy materials, including this proxy statement, our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, and a form of proxy card or voting instruction card. It is very important that your shares are represented and voted at the Annual Meeting. As explained in further detail in the Notice, your shares may be voted via a toll-free telephone number, on the Internet, or by signing, dating and returning the enclosed proxy c

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing